SEARCH

SEARCH BY CITATION

References

  • 1
  • 2
  • 3
    Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009; 183: 618697.
  • 4
    Deschuyteneer M, Elouahabi A, Plainchamp D, et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin. 2010; 6: 40719.
  • 5
    Garcon N, Morel S, Didierlaurent A, et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs. 2011; 25: 21726.
  • 6
    Evans JT, Cluff CW, Johnson DA, et al. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi529. Expert Rev Vaccines. 2003; 2: 21929.
  • 7
    Tiberio L, Fletcher L, Eldridge JH, et al. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. Vaccine. 2004; 22: 151523.
  • 8
    Ismaili J, Rennesson J, Aksoy E, et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol. 2002; 168: 92632.
  • 9
    Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol. 2010; 118: S127.
  • 10
    Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. Hum Vaccin. 2011; 7: 135973.
  • 11
    Kemp TJ, Safaeian M, Hildesheim A, et al. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix((R)). Vaccine. 2012; 31: 16570.
  • 12
    Sconocchia G, Keyvanfar K, El Ouriaghli F, et al. Phenotype and function of a CD56+ peripheral blood monocyte. Leukemia. 2005; 19: 6976.
  • 13
    Bigley V, Spence LE, Collin M. Connecting the dots: monocyte/DC and NK subsets in human peripheral blood. Blood. 2010; 116: 285960.
  • 14
    Anguille S, Smits EL, Cools N, et al. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med. 2009; 7: 109.
  • 15
    Anguille S, Lion E, Tel J, et al. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS ONE. 2012; 7: e51851.
  • 16
    Roothans D, Smits E, Lion E, et al. CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology. 2013; 2: e23037.
  • 17
    Wesa AK, Storkus WJ. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ. 2008; 15: 517.
  • 18
    Hanke N, Alizadeh D, Katsanis E, et al. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol. 2013; 33: 121.
  • 19
    Tay SK, Jenkins D, Singer A. Natural killer cells in cervical intraepithelial neoplasia and human papillomavirus infection. Br J Obstet Gynaecol. 1987; 94: 9016.
  • 20
    Koch J, Steinle A, Watzl C, et al. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013; 34: 18291.
  • 21
    Lion E, Smits EL, Berneman ZN, et al. NK cells: key to success of DC-based cancer vaccines? Oncologist. 2012; 17: 125670.
  • 22
    Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer. 2009; 9: 186.
  • 23
    Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 2008; 8: 16.
  • 24
    Textor S, Durst M, Jansen L, et al. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer. 2008; 123: 234353.
  • 25
    Lion E, Anguille S, Berneman ZN, et al. Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS ONE. 2011; 6: e20952.
  • 26
    Crosbie EJ, Kitchener HC. Cervarix–a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther. 2007; 7: 3916.
  • 27
    Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006; 24: 593749.
  • 28
    Lenz P, Day PM, Pang YY, et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol. 2001; 166: 534655.
  • 29
    Kim SH, Hur YJ, Lee SJ, et al. E6 and E7 fusion immunoglobulin from human papilloma virus 16 induces dendritic cell maturation and antigen specific activation of T helper 1 response. Biotechnol Lett. 2011; 33: 66371.
  • 30
    Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001; 8: 20920.
  • 31
    Dragicevic A, Dzopalic T, Vasilijic S, et al. The influence of CD40 ligation and interferon-gamma on functional properties of human monocyte-derived dendritic cells activated with polyinosinic-polycytidylic acid. Vojnosanit Pregl. 2011; 68: 3018.
  • 32
    Rudolf MP, Fausch SC, Da Silva DM, et al. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol. 2001; 166: 591724.
  • 33
    Bousarghin L, Hubert P, Franzen E, et al. Human papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells and colocalize with langerin in Langerhans cells. J Gen Virol. 2005; 86: 1297305.
  • 34
    Mohamadzadeh M, Berard F, Essert G, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med. 2001; 194: 101320.
  • 35
    Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012; 1: 894907.
  • 36
    Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun. 2003; 71: 2498507.
  • 37
    Le Poole IC, ElMasri WM, Denman CJ, et al. Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother. 2008; 57: 78997.
  • 38
    Korthals M, Safaian N, Kronenwett R, et al. Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med. 2007; 5: 46.
  • 39
    Tel J, Smits EL, Anguille S, et al. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood. 2012; 120: 393644.
  • 40
    Vujanovic L, Szymkowski DE, Alber S, et al. Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood. 2010; 116: 57583.